Better Care

Perlegen strives to enable physicians to treat patients more reliably and safely by matching genetic signatures to existing medications and to actionable disease risks. This approach could also improve the likelihood of success for clinical trials and potentially lead to breakthrough therapies by focusing studies on patients who are most likely to benefit from a particular treatment. The implications are enormous for clinical development, discovery research, marketing, reimbursement, and the practice of medicine itself.

Taking genetic variation to the clinic

Doctors need better information to make better diagnostic decisions. Perlegen discovers new genetic markers to provide that information and develops tests using those markers.

Genetic markers highlight personal characteristics that help doctors identify people who may be at risk for certain diseases or who may respond best to drugs now on the market for a range of important treatment situations such as cancer and heart attack.

Our expertise is in understanding human genetic variability. Our strength is in our ability to identify crucial genetic differences and to make this information available to doctors and patients through robust, reliable diagnostic tests that improve health, prolong lives, and save money.

A disciplined approach

There are many treatment situations that can benefit from genetically based diagnostic tests. When deciding among these situations we focus on a variety of factors, including unmet medical needs, the scientific value and reliability of our data, and the recommendations of our Clinical Strategic Advisory Board (CSAB).